Forgot Password?
Return to Course Listing

CME: Rewriting the script: from genetic mutation to therapeutic innovation in fibrodysplasia ossificans progressiva (FOP)

Activity Description / Statement of Need:

In this online, self-learning activity:

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic connective tissue disorder characterized by dysregulated chondrogenesis, with heterotopic ossification (HO) being the most typical feature. The global prevalence of FOP is estimated at 1.43 per million individuals, with a U.S. prevalence of 0.88 per million. FOP develops due to a mutation in the ACVR1 gene encoding the active receptor-like kinase (ALK2), with unique presenting symptoms including great toe malformations and the development of swelling in several areas of the body within the first decade of life.

Target Audience:

HCPs including but not limited to: pediatricians, pediatric orthopedic surgeons, endocrinologists, and medical geneticists; nurse practitioners and physician assistants practice in orthopedics, orthopedic surgery, or rheumatology; and any other healthcare professionals with an interest in or who clinically encounter patients with FOP.


Commercial Support Disclosure: This program is supported by an educational grant from Ipsen. 

This activity is free of charge.


Release Date: January 30, 2026 -- Expiration Date: January 30, 2028

Faculty: Eric T. Rush, MD, FAAP, FACMG, CCD

Agenda

Faculty introduction, disclosures

Introductory content: defining the context and challenge of FOP

  • Epidemiology
  • Clinical features, presentation, genetic testing, and pathophysiology
  • Difficulties of diagnosis
  • Prognosis

Current therapy for FOP 

  • Patient management

o   Prevention of flare-ups

-  Fall and viral illness prevention

-  Glucocorticoid prophylaxis

o   Evidence and consensus behind treating symptomatic lesions, and the roles of:

-  Glucocorticoids

-  NSAIDs

-  Retinoic acid receptor agonism

  • Preventative health maintenance: dental, audiological, and respiratory health
  • Emerging and future therapies
    • ACVR1 protein inhibition
    • Src kinase inhibition
    • Others
  • Challenges to successful FOP treatment and strategies for addressing them 
    • Transitioning from pediatric to adult care
    • The importance of the MDT
  • Patient case(s) 

Best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Define the clinical context and diagnostic challenges of FOP, including its epidemiology, clinical features, genetic etiology, natural history and pathophysiology.
  • Implement evidence-based patient management strategies for individuals with FOP, including prevention of flare-ups, treatment of active lesions, and preventative health maintenance.
  • Evaluate emerging therapeutic approaches for FOP and optimize multidisciplinary care delivery, including assessments of novel therapies, management of care transitions, and application through cases studies.

Accreditation

ACCME Activity #203378096

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

ABP MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

ABP MOC Credit Type: Lifelong Learning and Self-Assessment

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM and ABP.

Nurses: This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™, and the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ to meet the continuing education renewal requirements of nursing re-certification for APRNs and RN specialty. Some state nursing boards accept AMA PRA Category 1 Credit(s)™ for re-licensure requirements, some do not. Check your state board of nursing's CE requirements before applying credit from this course to your re-licensure.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Eric T. Rush, MD, FAAP, Professor of Pediatrics, University of Missouri‐University of Kansas School of Medicine, has received financial compensation from Alexion, AstraZeneca, Kyowa Kirin, Regeneron, Ipsen, Be Bio (relationship has ended), and Ultragenyx (relationship has ended) for consulting services; in addition to grant/research support from Alexion, AstraZeneca and Ultragenyx (relationship has ended); in addition to speakers bureau work from Alexion, AstraZeneca and Kyowa Kirin and a DSMB member for Inozyme.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Ipsen. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Management of Lennox-Gastaut syndrome (LGS) with strategies that have legs

Getting back in balance: restoring hormonal harmony in acromegaly

Best practices and opportunities for improvement in the medical management of Dravet syndrome: damn it, Dravet – what to do

Factoring updates in care and best practice into our management of hemophilia B